Neurodegenerative diseases represent a growing global health crisis, characterized by the progressive dysfunction and loss of neurons in the central nervous system.1 Among the pathological hallmarks of these debilitating conditions, the accumulation of neurofibrillary tangles (NFTs) composed of the microtubule-associated protein tau stands out as a critical factor in a diverse group of disorders known as tauopathies.1 Alzheimer's disease (AD), the most prevalent neurodegenerative disease, is also the most common tauopathy, where the extent and distribution of tau accumulation in the form of NFTs exhibit a strong positive correlation with the severity of cognitive impairment and dementia.1 Beyond AD, a spectrum of other tauopathies, including Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and various forms of frontotemporal dementia (FTD), are defined by the presence of abnormal tau inclusions.1 The sheer diversity of diseases associated with tau aggregates underscores the fundamental importance of deciphering the intricacies of tau pathology to pave the way for effective therapeutic interventions.The strong correlation between tau pathology and cognitive decline has spurred intense research efforts aimed at developing therapeutic interventions that specifically target tau protein and its aggregation into neurofibrillary tangles.3 Several promising therapeutic avenues are currently being explored, each with a unique mechanism of action.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related